Acquisitions:
1. Amgen has announced its acquisition of privately-held UK firm Dark Blue Therapeutics, a biotech advancing first-in-class, small molecule-targeted protein degraders for oncology, in a transaction valued at up to US$840 Million.
2. Artis BioSolutions to acquire Syngoi Technologies.
3. Bayer acquires Attralus’ cutting-edge cardiac amyloidosis imaging agents.
4. PAI Pharma acquires Nivagen to boost US injectable drug production.
Licensing:
1. Lupin signs exclusive agreement with Gan & Lee for Bofanglutide in India to commercialise and distribute.
2. Intas Pharmaceuticals has entered into an exclusive agreement with IntegriMedical for the introduction of a needle-free injection system for use in IVF and gynaecology treatments in India.
3. Lupin and Galenicum Sign License and Supply Agreement for Semaglutide in 23 Countries.
4. Viyash Scientific announces partnership with Boehringer Ingelheim to expand companion animal portfolio in India.
5. MS Pharma Group, a leading regional pharmaceutical company in the Middle East and North Africa (MENA) region, has signed a strategic partnership agreement with Hetero Pharma Group, a global pharmaceutical company of India, to localise five established biosimilars across key therapeutic areas, including oncology, immunology and hematology.
6. Insilico Medicine inks up to deal with Servier.
7. Novavax Enters in to License Agreement with Pfizer for Vaccine Development
8. SciNeuro and Novartis ink licensing and collaboration agreement for next generation therapeutics to treat Alzheimer’s disease.
Investments:
1. Novo Holdings Invests in Surya Hospitals to Strengthen Access to High-Quality Women’s and Children’s Healthcare in India
2. Rakuten Medical raises US$100 Million for photoimmunotherapy platform.
3. San Francisco-based biotech Mendra has emerged from stealth with an US$82 Million Series A financing round.
4. Proxima Raises US$80 Million Led by DCVC to Power the Next Generation of Proximity-Based Medicines.
Co-Development
1. Syngene International extends long-term research collaboration with Bristol Myers Squibb until 2035.
2. Cartography Biosciences, an oncology company advancing a pipeline of T-cell engaging bispecific and multi-specific antibody therapeutics, today announced a strategic collaboration with Pfizer to discover tumor selective antigens.
3. Bio-Sourcing and Zerion Pharma join forces to develop first HER2 oral monoclonal antibody against breast cancer.
HRV Pharma and Haleos Labs inks CDMO alliance to fast-track orphan drug & niche API development.
Aagami Updates:
1. Aagami’s CEO successfully participated in JPMorgan Healthcare Week and the Biotech Showcase in San Francisco, with over 35 productive meetings with decision makers.
2. New Client Win: US company addressing unmet medical needs in CNS, Cardio, Metabolic, and Inflammatory diseases
3. Contract Extension: Aagami received a contract extension from a US client, to complete an acquisition deal, which is in advanced stage of closure.
4. The next 2 partnering conferences Aagami will attend are:
a. DCAT WEEK | March 23-26, 2026 | New York City
b. ChinaBio™| April 28-29, 2026 | Shanghai
Select opportunities available with us:
For Partnering/Licensing/ Co-development:
1. [URGENT] US Licensing: FDA Approved Patented Lidocaine Patch using proprietary technology. 4 terms sheets in discussion and decision to be made within February 2026.
3. Seeking Co-development Partner/Investor/EPO supplier for Phase 3 stage Erythropoietin (EPO) patented asset for Resuscitation from Sudden Cardiac Arrest (A groundbreaking approach). By using the 351(A) dossier, an easy and quick path via 351 (K) Biosimilar approval for multiple indications may also be obtained.
4. Seeking Co-development/Out-Licensing: Phase 3 stage small molecule first-in-class eye drop to treat pre-surgical cataract (typically for patients 40 to 72 years of age).
6. Seeking Licensing/Partnering: Phase 2 Drug poised to revolutionize antiviral treatment; could be a single drug to treat all the "tripledemic" viruses (RSV, FLU, COVID). Also, Phase 2 trials are starting in Central Africa for MPOX. Very effective in Bird Flu and Measles too.
7. Smart Polymeric best-in-class delivery system platform with long-acting injectables pipeline. Seeking partnering and investment.
8. Dental gel (Marketed in the US & approved in EU) for Prevention & Treatment of Periodontitis, Gingivitis, & Caries. Featured in WSJ, FOX, NBC, ABC, GQ. Already a profit-making product. Licensing available.
For Acquisition:
1. A High Multiple ROI by acquiring small molecule clinical asset in rare diseases (sickle cell disease & thalassemia). (Two Phase 1 completed. Phase 2 ready). Low cost and quicker to market vs. Gene Therapy. Their previous asset was acquired for US$400 million.
2. [URGENT] Lucrative Opportunity to acquire IP Portfolio (bankruptcy disposition) of clinical stage First-in-Class Non-Opioid Analgesic. An offer is in finalization stage.
3. Available at a very reasonable price Mountain View Pharma (MVP) including its PharmaPEG® technology, product candidates, data package of ~20 drug candidates, IP etc. - for Next-generation biologics.
For Investment:
1. High ROI Opportunity to Invest in U.S.based medtech revolutionizing medical imaging with the world’s first portable, single-sided MRI platform (On the market for 4 years). Exit via an IPO, strategic M&A, or private equity buyout.
Hope you found the content useful. We welcome your feedback and queries.